“Leading NEALS is one of the things in my professional career I am proudest of,” says Shefner.
Trial News & Events
The University City Science Center in Philadelphia has awarded Temple two proof-of-concept grants: one for the development of a novel therapy for the treatment of amyotrophic lateral sclerosis (ALS) and another for the creation of a software program that will hone physicians’ ability to read and diagnose electroencephalography, or EEGs.
Neuralstem, Inc. has announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of ALS at Emory University Hospital in Atlanta, Georgia.
Cytokinetics Announces Publication of Results from Phase II Trials of Tirasemtiv in Patients with AL
Cytokinetics announced the publication of two manuscripts reporting data from two prior clinical trials of tirasemtiv, highlighting encouraging results.
NEALS Executive Committee Member Terry Heiman-Patterson, MD (Drexel University and the ALS Hope Foundation) leads this effort with the goal of providing advocacy training to PALS in and around the surrounding areas.
Dr. Jeff Rothstein provides medical and research insights during CNN's Three-Part Series on ALS with news anchor Suzanne Malveaux.
On behalf of the Executive and Abstract Committees for the 12th Annual NEALS Meeting, we would like to extend an invitation for members to submit an abstract for consideration for presentation at the Annual Meeting.
The event will take place at the Sandpearl Resort in Clearwater Beach, Florida, on Friday October 4th to Saturday October 5th. The deadline for nominations is August 2nd, 2013.
Knopp Biosciences, Inc. has agreed to donate placebo data from the phase III dexpramipexole trial to the award-winning PRO-ACT Platform, created by the NCRI and Prize4Life in partnership with NEALS. The dataset will be expanded to include treatment-arm data when research into dexpramipexole for ALS is complete. NCRI and NEALS in collaboration with Prize4life will continue to foster encouraging collaborative partnerships between academia and industry via this valuable resource.
Offering imminent hope for those with ALS, Genervon Biopharmaceuticals, an innovative biotechnology company announced today that it has received FDA approval for its broadly inclusive ALS clinical trial. Learn more.